AzTrials
AzTrials

Obese Patients (BMI ≥ 30 kg/m²)Si-OBANCT07020741

Stable Isotopes- Adults With Obesity

A study testing Indispensable Amino Acid Oxidation and Stable Isotope Oral Glucose Tolerance Test in people with Obese Patients (BMI ≥ 30 kg/m²) and Glucose Metabolism, run by University of Illinois at Urbana-Champaign at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

In a crossover design, 8 participants will receive caloric drinks containing stable isotopes. In one arm of the study, participants will consume 6 hourly drinks containing two stable isotopes. Repeated blood, breath, urine, and muscle biopsies will be taken. Read more about this study

Who is it for?
Ages 19 to 59 yearsHealthy volunteers can take part
What is being tested?
Indispensable Amino Acid Oxidation and Stable Isotope Oral Glucose Tolerance Test
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
1 siteUnited States
Study dates
12 Sep 2025to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 59 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • ages 19-59
  • Obese >/= 30 kg/m^2 and >/= 102 cm for males and >/= 88 cm for females
  • Godin Leisure-time or exercise questionnaire <14 units

Who cannot join

  • Pregnant or become pregnant
  • Any known food allergies
  • Smoker
  • Are physically active
  • Have any known metabolic diseases
  • Have been weight unstable within the last 6 months (lost or gained >10% of body mass)
  • Non eumenorrheic or on a hormonal birth control

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Nicholas Burd (Associate Professor), PhD contact

2172440970

naburd@illinois.edu

Gena L Irwin (Research Assistant), M.S contact

3608883281

genai2@illinois.edu

United States1 site, 1 recruiting
  • Freer Hall - University of Illinois

    Urbana, Illinois, 61801

    Nicholas Burd (Associate Professor), PhD, 2172440970, naburd@illinois.edu

    Gena L Irwin Research Assistant, M.S, 3608883281, genai2@illinois.edu

    Recruiting

Other trials in United States

About this study

Official title: Assessing Metabolic Health With Stable Isotope Tracer Techniques in Adults With Obesity

In a crossover design, 8 participants will receive caloric drinks containing stable isotopes. In one arm of the study, participants will consume 6 hourly drinks containing two stable isotopes. Repeated blood, breath, urine, and muscle biopsies will be taken. In the second arm, participants will consume 1 drink containing 75g glucose, labeled with two stable isotopes of glucose. Periodic blood and breath will be taken over three hours.

Read the detailed description
  1. Enrollment, Informed Consent, and Screening Questionnaires (Virtual): Prior to study enrollment, participants will be asked to read a digital copy of an informed consent document provided using the e-Consent framework through the Research Electronic Data Capture (REDCap) system. Should participants have any questions about the study after reading the document, they will be encouraged to contact the research team prior to providing informed consent. Upon provision of informed consent, participants will receive an email with questionnaires designed to assess eligibility for the study through REDCap. Specifically, participants will be asked to complete a health and medical history questionnaire, physical activity readiness questionnaire (PARQ), International Physical Activity Questionnaire Long Form (IPAQ), and Godin-Shephard Leisure-Time Physical Activity Questionnaire (LTPAQ). Information from the medical history questionnaire, PARQ, and LTPAQ will be used to assess exclusion criteria and the IPAQ be used to assess baseline habitual activity level. Upon completion of these questionnaires, the research team will review responses and determine eligibility. Should Participants be eligible, researchers will work with the participant to schedule subsequent visits
  2. Preliminary Testing (Visit 1): Participants will arrive for the preliminary testing session after an overnight fast.

Urine samples: 30mL of urine at time points -30 min, 0 min, 240 min, 300 min, and 360 min. Briefly, participants will be provided with a urine collection cup, alcohol wipes, and gloves and asked to fill the cup about 3/4 of they way.

Blood Collection: ~88 mL will be collected during the trial.

Breath Collection: At -30 minutes, 0 minutes, 120 minutes, 240 minutes, 300 minutes, 360 minutes, we will measure the air exhaled. To do this, participants breathe normally through a hose. Immediately after, they will exhale into a separate mouthpiece attached to a plastic bag.

Muscle Collection: A total of 2 muscle biopsies will be collected during the trial. The biopsy procedure involves removal of a small piece of muscle tissue using a sterile hollow needle (Bergström needle) and will be performed by Dr. Nicholas Burd under the auspices of Dr. Jared Willard, MD. Participants will rest on a bed and the area for the biopsy will be shaved, if required. Subsequently, the area will be sterilized using 4% chlorhexidine gluconate before 5 mL of local anesthetic (2% Xylocaine with 1:100,000 epinephrine) is injected subcutaneously with special care to avoid infiltrating the muscle. Once the anesthetic is active, a small incision will be made in the skin in order to create an opening through which to put the biopsy needle for tissue collection. Dr. Burd will quickly cut of a small piece of muscle. the subjects may feel a sensation of deep pressure in their leg. A sterile disposable drape will be placed under the participant's thigh and sterile gloves will be used for all biopsy procedures.

After the biopsy is completed, a trained research team member will apply pressure with sterile gauze until the bleeding stops (at least 15 minutes). Subsequently, the incision site will be closed using butterfly stitches (Steri-strips) following by application of a bandage. An elastic pressure wrap will be applied on top of the bandage in order to minimize the chance of bruising. Participants will then be instructed to leave the butterfly stitches and the pressure wrap on the wound for 96 and 24 hrs, respectively.

The participant will be provided with a "biopsy care kit" (described in section 10.1/Biopsy care kit) in order to properly care for the incision after leaving the laboratory. A member of the research team will contact the participants in the day following the trial to check on the healing process.

After blood, breath, and muscle samples of time 0, participants will drink the first of a series of drinks containing [13C]phenylalanine and [2H5]phenylalanine at a ratio of 1:10 with a 1:10 ratio of total tracer to tracee (naturally occurring phenylalanine) The first drink will be primed with NaH13CO2 (0.176 mg/kg) in addition to [13C]phenylalanine and [2H5]phenylalanine mixture. Drinks will be consumed every 30 minutes for the duration of the procedure.

These drink will also contain 1.2x estimated RMR calories (divided into 12 drinks)

VCo2: Carbon dioxide production (VCO2) will be determined from expired air sampled by open circuit spirometry using an on-line, computer-based acquisition system. Participants will breathe through a one-way, high velocity non-rebreathing valve. The volume of expired air is measured by a gas flow meter. The carbon dioxide concentrations of expired air are assessed by a carbon dioxide analyser. Analog data from the gas analyser and flow meter is digitized and sent to an IBM compatible PC for calculation of VCO2 converted to Standard Temperature and Pressure Dry. Immediately after VCO2 analysis is performed (5 min), subjects are asked to exhale into a separate mouthpiece attached to a plastic bag. This particular breath sample is stored in a sterile vacutainer for future analysis of stable isotope tracer enrichment in the breath. The measurement of carbon dioxide production (VCO2) and the measurement of tracer enrichment in the breath allow us to assess how much of the protein is used for energy, rather than for building skeletal muscle proteins. Subjects are not expected to experience any discomfort from this procedure, nor will it influence their physical well-being.

(Visit 4) Stable Isotope OGTT: within 7 days after the first trail participants will be asked to return to the lab for a second procedure.

Blood Collection: Blood collection procedures will be exactly as described above. There will be a total of 9 blood collections (time -10, 10, 20, 30, 60. 90, 120, 150, 180) minutes Breath Collection: Breath collection procedures will be exactly as described above. There will be a total of 9 breath collections (-10, 10, 20, 30, 60, 90, 120, 150, 180) minutes After the blood and breath collection for time -10 minutes, participants will be asked to consume a 75 g Glucose Drink dissolved in 250 ml of water enriched with [6,6_2H2]glucose and [13C6]glucose. As stated above, blood and breath samples will be taken periodically over the next 3 hours.

Being tested
Indispensable Amino Acid Oxidation, Stable Isotope Oral Glucose Tolerance Test

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Indispensable Amino Acid OxidationProcedure or surgery

    Also called IAAO

    Participants will ingest six hourly meals designed to provide 50% of the daily intake of 1.1 g·kgLBM. Additional energy (1.5x daily resting metabolic rate), carbohydrate (55%), and fat (35%) will be provided in beverages and protein-free cookies (for palatability). The first drink will contain priming doses of NaH13CO2 (0.176 mg·kg-1), [13C]phenylalanine (1.86 mg·kg-1), [2H5]phenylalanine (0.34 mg·kg-1) with all subsequent drinks containing 1.2 mg·kg-1 [13C]phenylalanine and 0.51 mg·kg-1 [2H5]phenylalanine.

  • Stable Isotope Oral Glucose Tolerance TestProcedure or surgery

    Also called Si OGTT

    Participants will consume a 75g glucose drink dissolved in 250 ml of water enriched with [6,6_2H2]glucose and [13C6]glucose.

Study groups in NCT07020741
Study groupRoleWhat they receive
IAAOExperimentalParticipants will ingest a series of 6 hourly beverages containing 50% of the daily intake of 1.1g/kg/day
Receives: Procedure: Indispensable Amino Acid Oxidation
SIOGTTExperimentalParticipants will consume one 75g glucose drink dissolved in 250 ml of water.
Receives: Procedure: Stable Isotope Oral Glucose Tolerance Test

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Define obesity-related whole body protein efficiency based of the IAAO method

    Amino Acid Oxidation of phenylalanine will be measured using the IAAO method by periodic ingestion of amino acid mixture. Trials will start at ~7:00 am (-30 minutes) with a total duration of 6.5 hours (390 minutes) Measurements of breath (-30, 0, 120, 240, 270, 300, 330 and 360 minutes), Urine (-30, 0, 240, 300, and 360 minutes), muscle biopsy (-30 and 360 minutes) and blood (-30, 0, 30, 60, 90,120, 180, 240, 300, and 360 minutes) will be used to determine the whole body efficiency of protein in obese populations.

    Measured: 0 - 6 hours observational period ingesting six hourly meals, within 1 week of preliminary testing. Baseline measures taken at --30 minutes.

  2. Assessment of oral glucose tolerance based on a dual tracer technique

    Measure glucose kinetics via [13C] and D5 Glucose over 3 hours to determine glucose tolerance. Trials will start at ~7:00 am (-10 minutes) and last ~ 3 hours. (190 minutes)

    Measured: 0- 3 hour observational period. Within 1 week of the prospective arm. Baseline taken at -30 minutes.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jun 2025
  2. Study start12 Sep 2025
  3. Primary completion30 Aug 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
The study will employ a crossover model where they will complete 2 of 2 conditions, in a randomized order.
Masking
None (open label)
Enrolment
8 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07020741
Sponsor's protocol ID
IRB25-0166
Other IDs
RB25064
Acronym
Si-OBA
Status last verified
Jun 2025
First submitted
9 May 2025
Last updated
29 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Because it is not planned to published in any ICMJE journal.

Questions about this trial

What is this clinical trial studying?

A study testing Indispensable Amino Acid Oxidation and Stable Isotope Oral Glucose Tolerance Test in people with Obese Patients (BMI ≥ 30 kg/m²) and Glucose Metabolism, run by University of Illinois at Urbana-Champaign at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Nicholas Burd (Associate Professor), PhD (2172440970, naburd@illinois.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Define obesity-related whole body protein efficiency based of the IAAO method (time frame: 0 - 6 hours observational period ingesting six hourly meals, within 1 week of preliminary testing. Baseline measures taken at --30 minutes.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in